JERUSALEM, Dec. 6, 2019 /PRNewswire/ -- Intec
Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today
announces that the Company management will be participating in
the 12th Annual LD Micro Main Event investor
conference.
12th Annual LD Micro Main Event
Date: December 10-12, 2019
Company Presentation: Wednesday, December 11, 2019 at
8:40 am (PST)
Location: The Luxe Sunset Bel Air Hotel, Bel Air, CA
Presenter: Jeffrey A.
Meckler, Vice Chairman and Chief Executive Officer
of Intec Pharma
Format: Corporate presentation and One-on-One Investor
Meetings
Mr. Meckler's presentation will be webcast live and will be
accessible through the Events section of Intec
Pharma's website at www.intecpharma.com, where it will
also be archived for a period of time.
"This year's Main Event is our largest event to date, with 275
companies set to present and meet with investors," stated
Chris Lahiji, President of LD Micro.
"Even though LD has emerged as one of the largest and most
influential organizations in the space, our focus has never
deviated from showcasing some of the more interesting businesses in
the world to our ever-growing community. Investor interest in our
events has also never been stronger, and that goes for our
commitment to philanthropy as well."
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out
as a newsletter highlighting unique companies has transformed into
several influential events annually (Invitational, Summit, and Main
Event). In 2015, LDM launched the first pure microcap index
(the LDMi) to exclusively provide intraday information on the
entire sector. LD will continue to provide valuable tools for the
benefit of everyone in the small and micro-cap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit
www.ldmicro.com for more information.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is in late-stage development for the treatment of
Parkinson's disease symptoms in advanced Parkinson's disease
patients, and AP-cannabinoids, an Accordion Pill to deliver either
or both of the primary cannabinoids contained in Cannabis sativa,
cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain
indications. In addition, the Company has a feasibility agreement
for the development of a custom-designed Accordion Pill for a
proprietary compound with Novartis Pharmaceuticals and a research
collaboration with Merck & Co.
For more information, visit www.intecpharma.com. Intec Pharma
routinely posts information that may be important to investors in
the Investor Relations section of its website.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward looking statements about our
expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as
"believe", "expect", "intend", "plan", "may", "should", "could",
"might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to, the following: our limited operating
history and history of operating losses, our ability to continue as
a going concern, our ability to obtain additional financing, our
ability to successfully operate our business or execute our
business plan, our ability to enter into collaborative, licensing,
and other commercial relationships and on terms commercially
reasonable to us, the timing and cost of our clinical trials, the
completion and receiving favorable results in our clinical trials,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to protect and maintain our
intellectual property and licensing arrangements, our ability to
develop, manufacture and commercialize our product candidates, the
risk of product liability claims, the availability of
reimbursement, and the influence of extensive and costly government
regulation and our ability to remain listed on the Nasdaq Capital
Market. More detailed information about the risks and uncertainties
affecting us is contained under the heading "Risk Factors" included
in our most recent Annual Report on Form 10-K filed with
the SEC on February 27, 2019, and in other filings
that we have made and may make with the Securities and
Exchange Commission in the future.
Intec Pharma Investor Contact:
Anne Marie
Fields
VP-Corporate Communications & Investor Relations
646-200-8808
amf@intec-us.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-to-present-at-ld-micros-12th-annual-main-event-300970515.html
SOURCE Intec Pharma Ltd.